Leerink Partnrs Has Bullish Forecast for XENE Q2 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at Leerink Partnrs lifted their Q2 2025 EPS estimates for Xenon Pharmaceuticals in a note issued to investors on Tuesday, May 13th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will earn ($1.10) per share for the quarter, up from their prior estimate of ($1.14). The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.20) EPS and FY2025 earnings at ($4.30) EPS.

Several other analysts also recently commented on the stock. StockNews.com upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday. HC Wainwright restated a “buy” rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday. The Goldman Sachs Group decreased their price objective on shares of Xenon Pharmaceuticals from $60.00 to $52.00 and set a “buy” rating on the stock in a research report on Thursday, April 17th. Royal Bank of Canada decreased their price objective on shares of Xenon Pharmaceuticals from $58.00 to $55.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $54.82.

Xenon Pharmaceuticals Trading Up 2.4%

XENE opened at $30.29 on Friday. Xenon Pharmaceuticals has a 1-year low of $26.74 and a 1-year high of $46.00. The company has a market capitalization of $2.32 billion, a PE ratio of -10.74 and a beta of 1.21. The firm’s 50 day simple moving average is $34.10 and its two-hundred day simple moving average is $37.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.07. The company had revenue of $7.50 million for the quarter, compared to the consensus estimate of $1.64 million. During the same quarter last year, the company earned ($0.62) EPS.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC grew its position in Xenon Pharmaceuticals by 8.8% in the fourth quarter. FMR LLC now owns 7,525,290 shares of the biopharmaceutical company’s stock worth $294,991,000 after acquiring an additional 607,606 shares in the last quarter. Driehaus Capital Management LLC grew its position in Xenon Pharmaceuticals by 1.4% in the first quarter. Driehaus Capital Management LLC now owns 4,584,859 shares of the biopharmaceutical company’s stock worth $153,822,000 after acquiring an additional 64,264 shares in the last quarter. Wellington Management Group LLP grew its position in Xenon Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 3,789,197 shares of the biopharmaceutical company’s stock worth $127,128,000 after acquiring an additional 11,586 shares in the last quarter. Braidwell LP grew its position in Xenon Pharmaceuticals by 7.6% in the fourth quarter. Braidwell LP now owns 2,913,964 shares of the biopharmaceutical company’s stock worth $114,227,000 after acquiring an additional 206,709 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Xenon Pharmaceuticals by 12.3% during the 4th quarter. Janus Henderson Group PLC now owns 2,866,755 shares of the biopharmaceutical company’s stock worth $112,425,000 after purchasing an additional 314,363 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.